ClinicalTrials.gov
public full text
Public Domain
A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)
The purpose of this study is to determine if Pneumovax™ 23 (V110) is safe and immunogenic in participants from the Russian population who are 50 years of age and older or 2 to 49 years of age and at increased risk for pneumococcal disease
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Systems Biology of PNEUMOVAX®23 and PREVNAR 13®#910656
- A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013)#208277
- Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Population#300316
- Safety and Immune Response Study of an Investigational Pneumococcal Vaccine.#895860
- 13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico#217094
Record · ID 859748
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive